
In the Alzheimer’s disease brain, the amyloid beta peptide clumps together to form hardened plaques between nerve cells.
Key Takeaways
- Researchers have developed a method based on artificial intelligence that rapidly identifies currently available medications that may treat Alzheimer’s disease.
- The method also reveals potential new treatment targets for the disease.
Independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies.
Mark Albers, MD, PhD
Associate Director, Massachusetts Center for Alzheimer Therapeutic Science, Massachusetts General Hospital
New treatments for Alzheimer’s disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. Now a team at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has developed an artificial intelligence–based method to screen currently available medications as possible treatments for Alzheimer’s disease. The method could represent a rapid and inexpensive way to repurpose existing therapies into new treatments for this progressive, debilitating neurodegenerative condition. Importantly, it could also help reveal new, unexplored targets for therapy by pointing to mechanisms of drug action.
“Repurposing FDA-approved drugs for Alzheimer’s disease is an attractive idea that can help accelerate the arrival of effective treatment—but unfortunately, even for previously approved drugs, clinical trials require substantial resources, making it impossible to evaluate every drug in patients with Alzheimer’s disease,” explains Artem Sokolov, PhD, director of Informatics and Modeling at the Laboratory of Systems Pharmacology at HMS. “We therefore built a framework for prioritizing drugs, helping clinical studies to focus on the most promising ones.”
In an article published in Nature Communications, Sokolov and his colleagues describe their framework, called DRIAD (Drug Repurposing In Alzheimer’s Disease), which relies on machine learning—a branch of artificial intelligence in which systems are “trained” on vast amounts of data, “learn” to identify telltale patterns and augment researchers’ and clinicians’ decision-making.
DRIAD works by measuring what happens to human brain neural cells when treated with a drug. The method then determines whether the changes induced by a drug correlate with molecular markers of disease severity.
The approach also allowed the researchers to identify drugs that had protective as well as damaging effects on brain cells.
“We also approximate the directionality of such correlations, helping to identify and filter out neurotoxic drugs that accelerate neuronal death instead of preventing it,” says co-first author Steve Rodriguez, PhD, an investigator in the Department of Neurology at MGH and an instructor at HMS.
DRIAD also allows researchers to examine which proteins are targeted by the most promising drugs and if there are common trends among the targets, an approach designed by Clemens Hug, PhD, a research associate in the Laboratory of Systems Pharmacology and a co-first author.
The team applied the screening method to 80 FDA-approved and clinically tested drugs for a wide range of conditions. The analysis yielded a ranked list of candidates, with several anti-inflammatory drugs used to treat rheumatoid arthritis and blood cancers emerging as top contenders. These drugs belong to a class of medications known as Janus kinase inhibitors. The drugs work by blocking the action of inflammation-fueling Janus kinase proteins, suspected to play a role in Alzheimer’s disease and known for their role in autoimmune conditions. The team’s analyses also pointed to other potential treatment targets for further investigation.
“We are excited to share these results with the academic and pharmaceutical research communities. Our hope is that further validation by other researchers will refine the prioritization of these drugs for clinical investigation,” says Mark Albers, MD, PhD, the Frank Wilkins Jr. and Family Endowed Scholar and associate director of the Massachusetts Center for Alzheimer Therapeutic Science at MGH and a faculty member of the Laboratory of Systems Pharmacology at HMS. One of these drugs, baricitinib, will be investigated by Albers in a clinical trial for patients with subjective cognitive complaints, mild cognitive impairment, and Alzheimer’s disease that will be launching soon at MGH in Boston and at Holy Cross Health in Fort Lauderdale, Florida. “In addition, independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies,” says Albers.
Original Article: Artificial intelligence reveals current drugs that may help combat Alzheimer’s disease
More from: Massachusetts General Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Artificial intelligence to identify new drug treatments
- 7 medical breakthroughs that gave us hope in 2023
From gene therapy to Alzheimer’s treatment, predicting pancreatic cancer to pioneering reproduction methods, there were many promising discoveries in 2023 that will influence health and medicine ...
- MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, today launched its AIDDISON™ drug discovery software, the first ...
- Medicine, Technology and the End of Cancer
Advancements in technology and science often occur in parallel silos, but when they converge, the results can be groundbreaking. The merging of mRNA and artificial intelligence exemplifies such a ...
- A New Trick Uses AI to Jailbreak AI Models—Including GPT-4
Adversarial algorithms can systematically probe large language models like OpenAI’s GPT-4 for weaknesses that can make them misbehave.
- AI in health care: The perils of Biden's executive order
In an audacious move, the White House recently issued a staggering 111-page executive order on artificial intelligence. The regulatory scope of the order is alarming.
Go deeper with Google Headlines on:
Artificial intelligence to identify new drug treatments
[google_news title=”” keyword=”artificial intelligence to identify new drug treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
New Alzheimer’s treatment targets
- New Protein Aggregates Found in Cases of Early Onset Dementia
However, for around 10 percent of cases of frontotemporal dementia (FTD), the most common form of dementia after Alzheimer’s disease, the rogue protein hasn’t been known. Now, scientists headed by a ...
- Novel drug delivery system developed for Gouteng compound for Alzheimer's disease treatment
A research team led by Hong Kong Baptist University (HKBU) has developed a novel drug delivery system for Alzheimer's disease (AD). The researchers have engineered exosomes, extracellular vesicles ...
- Mystery Early-Onset Dementia Marker Identified
The discovery transforms our understanding of the molecular basis of this type of dementia and provides hope for treatments and diagnostic tests in the future.
- New protein linked to early-onset dementia identified
Most neurodegenerative diseases, including dementias, involve proteins aggregating into filaments called amyloids. In most of these diseases, researchers have identified the proteins that aggregate, ...
- Medicare Coverage Of PET Scans For People With Alzheimer’s Disease: What To Know
Positron emission tomography (PET) beta-amyloid imaging is a vital tool in the diagnosis and treatment of Alzheimer’s disease. Fortunately, the Centers for Medicare and Medicaid Services (CMS) ...
Go deeper with Google Headlines on:
New Alzheimer’s treatment targets
[google_news title=”” keyword=”new Alzheimer’s treatment targets” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]